Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Overview of attention for article published in BMC Medicine, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 9,518 followers.

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors https://t.co/FNby17A7UI https://t.co/FKm9yNDL4o

11 Nov 2022

Reply Repost Favourite

How to overcome immune checkpoint inhibitors (ICIs) treatment resistance in solid tumours? Evidence in a murine model suggests optimized dose of selective HDAC inhibitor tucidinostat can overcome anti-PD-L1 antibody resistance: https://t.co/cGgcqE8kBZ ht

09 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.